Novartis splashes the cash in Asia
Novartis is splashing its cash in Asia, intending to invest $100m (€79m) in China and INR5bn (€90m) in India to establish large new R&D centres.
Novartis is splashing its cash in Asia, intending to invest $100m (€79m) in China and INR5bn (€90m) in India to establish large new R&D centres.
Rising contract research organisation (CRO) and investigator fees are being blamed in a new report as largely contributing to the skyrocketing cost of new drugs.
A new improved range of urethane-based floor systems that is claimed to help pharma manufacturers reduce the level of bacteria contamination in their production environment has been launched.